Premium
A phase 2 trial of regorafenib as a single agent in patients with chemotherapy‐refractory, advanced, and metastatic biliary tract adenocarcinoma
Author(s) -
Sun Weijing,
Patel Anuj,
Normolle Daniel,
Patel Krishna,
Ohr James,
Lee James J.,
Bahary Nathan,
Chu Edward,
Streeter Natalie,
Drummond Summer
Publication year - 2019
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31872
Subject(s) - regorafenib , medicine , refractory (planetary science) , chemotherapy , biliary tract , metastatic adenocarcinoma , oncology , adenocarcinoma , phases of clinical research , gastroenterology , cancer , colorectal cancer , physics , astrobiology
Background Biliary tract cancers are rare, aggressive neoplasms. Most patients present with advanced/unresectable or metastatic disease at diagnosis, and no second‐line regimen has demonstrated clinical benefit. This was a phase 2 study evaluating the efficacy and safety of regorafenib in patients who had advanced/unresectable or metastatic disease after receiving standard therapy. Methods In this single arm‐study, patients with advanced/unresectable or metastatic biliary tract cancer who failed at least 1 line of systemic chemotherapy received regorafenib once daily on a schedule of 21‐days on/7‐days off in a 28‐day cycle. Patients initially received a standard 160 mg dose. After toxicity assessments in the first 3 patients, the dose was reduced to 120 mg for subsequent patients, as preplanned. The primary endpoint was progression‐free survival (PFS). Secondary objectives included overall survival (OS), the objective response rate, and the disease control rate. Results Forty‐three patients received at least 1 dose of regorafenib, and 34 patients who received at least 1 cycle of treatment were evaluable for tumor response. The median PFS was 15.6 weeks (90% confidence interval, 12.9‐24.7 weeks), and the median OS was 31.8 weeks (90% confidence interval, 13.3‐74.3 weeks), with survival rates 40% at 12 months and 32% at 18 months. A partial response was achieved in 5 patients (11%), and 19 had stable disease (44%), for a disease control rate of 56%. The toxicity profile was as expected, with grade 3 and 4 adverse events reported in 40% of patients. The most common toxicities were hypophosphatemia (40%), hyperbilirubinemia (26%), hypertension (23%), and hand‐foot skin reaction (7%). Conclusions The current results suggest promising efficacy of regorafenib in patients with chemotherapy‐refractory, advanced/metastatic biliary tract cancer, warranting further studies to confirm its clinical efficacy. There is a clear unmet need for effective therapies in patients who have advanced and metastatic biliary tract cancer.